Altium Capital Management focuses on long-term investments in Healthcare companies. We provide growth capital to private and public companies developing novel technologies for human health. Our CEO, Jacob Gottlieb, has over 20 years of healthcare hedge fund, private equity, and venture capital investing experience, developing successful teams of investment professionals and business management staff. Our team includes a mix of scientific professionals and experienced fund managers who work together to uncover unique investment insights to produce superior returns in the long term.

At Altium Capital, we look for intelligent, motivated people who want to learn and enrichen their careers. We pride ourselves on our collaborative team approach, positive culture and firmwide integrity. Our spirit of sharing creates intellectual growth and opportunities for career progression  – we invest in our people with the long-term mentality of apprenticeship and development.

Our investment universe is mostly concentrated in therapeutics, within private ventures, small-cap and micro-cap public companies. We look for these companies to have transformative catalysts in the years to come, many of which are raising capital from institutional investors for the first time. Our growth capital supports early-stage ventures in the pre-clinical development phases, with a view to long-term partnerships and multiple rounds of financing into those firms. Altium also helps companies attract additional capital through our network of like-minded investors. Our research and due diligence gives us the confidence to invest long term in promising new technologies.

Selected Portfolio Companies

  • Antios Therapeutics

    Antios Therapeutics

    Founded in 2018, Antios Therapeutics is a biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.

  • Cerevel Therapeutics

    Cerevel Therapeutics

    Cerevel Therapeutics is working relentlessly to find paths through complexity in an effort to bring real progress and new treatment options to people living with a broad range of neuroscience diseases.

  • Chemomab Therapeutics

    Chemomab Therapeutics

    Chemomab Therapeutics is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high unmet need that involve Inflammation and fibrosis

  • eGenesis


    At eGenesis, we are committed to ending the global transplant shortage and transforming the treatment of organ failure.

  • Gemini Therapeutics

    Gemini Therapeutics

    Gemini Therapeutics is a precision medicine company focused on the development of new therapies for dry AMD.

  • Hummingbird Bioscience

    Hummingbird Bioscience

    We are a clinical-stage biotechnology company with a proprietary and differentiated Rational Antibody Discovery (RAD) platform, developing a broad pipeline of novel, precision therapeutics for the treatment of cancer and autoimmune disease.

  • Hyperfine


    At Hyperfine, Rothberg and his team of scientists and engineers set out to put MR imaging within reach of every patient regardless of location—in any healthcare facility in any country across the globe.

  • Immunovant


    Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

  • Ocuphire Pharma

    Ocuphire Pharma

    Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders.

  • Palisade Bio

    Palisade Bio

    Palisade Bio is a late-stage biopharma company advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage.

  • Quoin


    Quoin is an emerging specialty pharmaceutical company dedicated to developing therapeutic products for the treatment of rare and orphan diseases for which no FDA-approved treatments currently exist.

  • Sagimet Biosciences

    Sagimet Biosciences

    A clinical-stage pharmaceutical company developing novel therapeutics to treat important diseases such as non-alcoholic steatohepatitis (NASH) and various cancers.

  • Seelos Therapeutics

    Seelos Therapeutics

    Seelos intends to become a leading biopharmaceutical company focused on neurological and psychiatric disorders, including orphan indications

  • Sonnet BioTherapeutics

    Sonnet BioTherapeutics

    At Sonnet BioTherapeutics, we are taking the fight directly to cancer.

  • Timber Pharmaceuticals

    Timber Pharmaceuticals

    Timber was formed around the collaboration of three companies with demonstrated experience in all phases of drug development and clinical research.

  • Vincerx Pharma

    Vincerx Pharma

    Vincerx Pharma is a clinical-stage biopharmaceutical company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.

  • Yumanity Therapeutics

    Yumanity Therapeutics

    Yumanity Therapeutics is a clinical-stage biopharmaceutical company that is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform.

Chief Investment Officer


Jacob Gottlieb, MD, CFA, PRM is the Managing Partner and Chief Investment Officer of Altium Capital Management, which he founded in 2017. Jacob has over 20 years of hedge fund, private equity, and venture capital investing experience, including developing successful teams of investment professionals and business management staff.

Prior to founding Altium, Dr. Gottlieb founded Visium Asset Management in 2005, a successful spinout from Balyasny Asset Management. Under his leadership, Visium grew to approximately $8 billion AUM, employing over 175 people in US & EU, and became one of the premier healthcare investors in the world – managing assets for public and private pension funds, corporate investment offices, endowments and foundations, and ultra high net worth families. As Chief Investment Officer, he led a team of more than 85 investment professionals and developed institutional-level investment processes. Visium’s flagship product, Visium Balanced Fund (healthcare focused equities) generated industry-leading results, including peak assets under management of approximately $4 billion and approximately 15% average annual returns from 2001 to 2015 on a market-neutral portfolio.

Dr. Gottlieb led the creation and Visium launched other public equity and credit hedge fund products, a UCITS fund for European investors, a 40-Act alternative mutual fund, and customized products for key institutional investors. Additionally, Visium acquired and re-launched other hedge fund and private equity products, including the product that was launched as Visium Healthcare Partners, a specialty finance business focused on royalties for commercialized therapeutics (subsequently spun out to become Madryn Asset Management).

Prior to founding Visium, Dr. Gottlieb was the Healthcare Portfolio Manager and Partner at Balyasny Asset Management where he built his team to over 20 investment professionals, then spinning out to form Visium. Before joining Balyasny, he was a Portfolio Manager at Merlin BioMed, where he contributed to a 200% gross return in a single year. Dr. Gottlieb started his investment career as a buyside analyst at Sanford C. Bernstein (now AllianceBernstein), covering global healthcare.

Dr. Gottlieb graduated magna cum laude from Brown University, then attended New York University Medical School earning his medical degree in 1997. He obtained his CFA charter in 2001, and his PRM designation from the Professional Risk Managers' International Association in 2010.


We are always looking for exceptional and talented people to join the team at Altium Capital Management. If you are interested in joining the Altium Capital Management team, please submit your resume to with the role in subject line.


Our Team

Altium’s core values are teamwork, continuous improvement, and integrity. The team is a combination of medical, scientific, and industry experts working with professional investors, whose work synthesizes into high-conviction decisions for long-term investments.


Contact Us


152 W 57th Street
FL 20
New York, NY 10019

Carnegie Hall Tower, 57th Street between 6th and 7th Avenue

Altium Capital Management